Tag
This study evaluates the six-month effectiveness and long-term retention of TNF, IL-17, and IL-23 inhibitors in psoriatic arthritis, revealing comparable efficacy and persistence across biologic classes and highlighting disease duration as
The GOLMePsA trial found no significant difference in disease activity at 24 weeks when adding golimumab to methotrexate and steroids for early PsA. However, the triple therapy significantly reduced the need for rescue corticosteroids, high
In the multicenter UPJOINT observational study, upadacitinib produced rapid and sustained improvements in minimal disease activity in both oligo- and polyarticular psoriatic arthritis over 48 weeks, with a safety profile consistent with pri
The UPsA activity and damage ultrasound scores (and a simplified sUPsA) were developed and internally validated in 312 PsA patients; they correlate moderately with clinical measures, are responsive to change (SRM overall 0.63; 1.03 in MDA a
The STAMP randomized trial found that a treat‑to‑target strategy starting with secukinumab plus methotrexate did not achieve superior 6‑month ACR50 rates versus a conventional methotrexate‑first step‑up approach; 12‑month outcomes were simi
A phase 2 randomized, placebo‑controlled trial found sonelokimab — a nanobody that inhibits IL‑17A and IL‑17F — produced significant improvements in joint and skin outcomes in active psoriatic arthritis versus placebo, with an acceptable sh
This article evaluates the prevalence and infection risks associated with combination targeted therapies in adults with psoriatic arthritis, revealing no significant increase in serious or opportunistic infections compared to standard thera
Early secukinumab use in newly diagnosed psoriatic arthritis delivers faster clinical improvement at 3 months compared to standard care, but this advantage diminishes by 6 months and beyond.
